Novartis: transcript of exhibit 05 (page 2)
This is a transcription of the visible text of the published, redacted document page on the Novartis evidence record. It was generated on 2026-09-17 by optical character recognition of the published image, never of the original. Where the published image carries a redaction box, the transcript says [REDACTED] (1 on this page). OCR can misread characters; the image governs.
SHA-256 of the transcribed file: a7c2b4d7bf3b3fbc4a6fb29b1535ed0d4068f7293f71f552f52c4a750f5ee9c4. The SHA-256 confirms the downloaded file matches the published file; it does not independently authenticate the underlying agreement.
Transcript
IN WITNESS WHEREOF, the parties hereto have caused this Task Order 2011-1 to be
executed by their respective duly authorized representatives as of the day and year first
above written.
NOVARTIS INSTITUTES FOR BIOMEDICAL EPC Group
RESEARCH, INC.
[SIGNATURE REDACTED - ORIGINAL [REDACTED] [SIGNATURE REDACTED - ORIGINAL
RETAINED BY EPC GROUP] [REDACTED] RETAINED BY EPC GROUP]
By: ee By: [REDACTED]
[CLIENT SIGNATORY ——
Name NAME REDACTED] Name: Errin O’Connor
Title: Executive Director Title: Founder & CEO
O'Connor Enterprise Group, Inc., doing business as EPC Group, is the legal contracting entity for the engagements documented here.